IDEAYA Biosciences, Inc.
IDYA$1.80B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO131 employees
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
6
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
IDYA News
Catalyst Timeline
6 upcoming, 0 past
Drug Pipeline
Crizotinib
Metastatic Uveal Melanoma
Darovasertib
Uveal Melanoma
IDE196
Metastatic Uveal Melanoma
IDE574
ER+, HER 2- Breast Cancer
IDE849
Small-cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Crizotinib | Phase 3 | Metastatic Uveal Melanoma | - | - |
Darovasertib | Phase 3 | Uveal Melanoma | - | - |
IDE196 | Phase 3 | Metastatic Uveal Melanoma | - | - |
IDE574 | Phase 2 | ER+, HER 2- Breast Cancer | - | - |
IDE849 | Phase 2 | Small-cell Lung Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply